Eamonn Brady MPSI provides an overview of blood-thinners and why anticoagulant interactions remain a major pharmacy issue
Part 1: The transition from warfarin to NOACs
Anticoagulants remain among the highest-risk medicines encountered in both community and hospital pharmacy practice because even relatively minor interactions can result in serious bleeding or thrombotic complications. Their use has risen considerably over the past decade, largely due to increasing rates of atrial fibrillation, venous thromboembolism, cardiovascular disease, and an ageing population with multiple comorbidities.
For many years, warfarin was the dominant oral anticoagulant used in Ireland and internationally. However, NOACs (non-vitamin K oral anticoagulants), including apixaban, rivaroxaban, dabigatran, and edoxaban, are now more commonly prescribed for many indications. This shift has largely occurred because NOACs provide a more consistent anticoagulant response with less need for ongoing laboratory surveillance compared with warfarin.
Despite these advantages, NOACs are not free from clinically important interactions. Pharmacodynamic interactions may increase bleeding risk through additive effects, while pharmacokinetic interactions can alter drug concentrations through changes in absorption, metabolism, or elimination.
Warfarin – why has its use declined, but why interactions still matter
Why NOACs became preferred
Warfarin remains one of the most clinically significant medicines associated with drug interactions, despite its reduced use in routine anticoagulation practice. For decades, it was the standard oral anticoagulant for conditions such as atrial fibrillation, venous thromboembolism, and prosthetic heart valves. However, prescribing patterns have changed substantially following the introduction of NOACs.
NOACs, including apixaban, rivaroxaban, dabigatran, and edoxaban, are now preferred for many patients because they offer more predictable anticoagulant effects and do not usually require routine INR monitoring. In contrast, warfarin has a limited margin between under- and over-anticoagulation, meaning small changes in drug levels can significantly increase either bleeding risk or clotting risk. Warfarin is also heavily affected by CYP450 hepatic metabolism, dietary vitamin K intake, alcohol consumption, acute illness, and numerous medicine interactions.
Despite declining use, pharmacists must remain particularly vigilant with warfarin because interaction severity can be substantial. Significant INR elevation may occur following the introduction of commonly used medicines, including antibiotics, antifungals, NSAIDs, and herbal products. Warfarin nevertheless remains important in selected patient groups, particularly those
with mechanical heart valves, severe renal impairment, or antiphospholipid syndrome. Frequent monitoring and patient education remain essential in minimising avoidable complications.
Part 2: Drug interactions with anticoagulants
OTC analgesics and anti- inflammatory medicines NSAIDs and gastrointestinal bleeding risk
Over-the-counter (OTC) analgesics and anti-inflammatory medicines remain among the most common causes of preventable anticoagulant-related bleeding complications encountered in pharmacy practice. Many patients incorrectly assume that medicines purchased without prescription are inherently safe, particularly when used short term. However, even brief NSAID exposure can significantly increase bleeding risk in patients receiving warfarin or NOAC therapy.
Ibuprofen, naproxen, and diclofenac are particularly important because they impair platelet aggregation while simultaneously damaging the gastrointestinal mucosa. When combined with anticoagulants, this creates a substantial increase in gastrointestinal bleeding risk. The risk becomes even greater in elderly patients, those with previous peptic ulcer disease, concurrent corticosteroid therapy, or dual antiplatelet treatment.
Aspirin-containing OTC products also remain problematic. Some patients may unintentionally duplicate therapy when taking low-dose prescribed aspirin alongside OTC flu or pain remedies containing additional aspirin. Although paracetamol is usually considered the safest first-line analgesic option, prolonged high-dose use may still increase INR in warfarin- treated patients.
Cold and flu preparations: Hidden anticoagulant risks Combination products and unintentional duplication
Cold and flu preparations frequently present interaction risks for anticoagulated patients because many combination products contain multiple active ingredients that patients may not
fully recognise. Community pharmacists are therefore often the final safeguard in identifying potentially dangerous combinations before purchase. This is particularly important during winter months, when patients commonly self- medicate for short-term viral illnesses.
Many OTC cold and flu products contain NSAIDs such as ibuprofen or aspirin, both of which may significantly increase bleeding risk when combined with warfarin or NOAC therapy. Patients may unintentionally duplicate therapy by taking several products simultaneously, particularly where branding differs despite similar active ingredients. Aspirin-containing effervescent products and flu sachets remain especially important examples.
Decongestants such as pseudoephedrine and phenylephrine do not directly increase anticoagulant activity but may still pose cardiovascular concerns in older patients with hypertension, atrial fibrillation, or ischaemic heart disease. Acute infection itself may also destabilise anticoagulant control through reduced oral intake, fever, or concurrent antibiotic use, further increasing clinical complexity.
Herbal remedies, vitamins, and supplements Common supplements associated with bleeding risk
Herbal medicines and dietary supplements are frequently overlooked when assessing anticoagulant interactions, despite their potential to significantly alter bleeding risk. Many patients do not consider supplements to be medicines and may therefore fail
Although generally beneficial, PPIs may still contribute to interactions in certain situations
to mention them during medication reviews or OTC consultations. Several commonly used herbal products possess clinically important anticoagulant or antiplatelet effects. Ginkgo biloba, garlic supplements, fish oils, turmeric, and ginseng may all contribute to increased bleeding risk through effects on platelet function or coagulation pathways. St John’s Wort is particularly important because it induces CYP3A4 and P-glycoprotein pathways, potentially reducing plasma concentrations of certain NOACs and compromising anticoagulant efficacy.
Warfarin interactions remain especially problematic due to its sensitivity to changes in hepatic metabolism and vitamin K balance. Supplements containing vitamin K
may reduce INR, while other herbal products may unpredictably increase anticoagulant activity. Patients should therefore be encouraged to consult their pharmacist before initiating any new supplement or complementary therapy.
Gastrointestinal medicines
Effects on absorption and gastrointestinal protection Gastrointestinal medicines are frequently prescribed alongside anticoagulants, particularly in older patients at increased risk of dyspepsia or gastrointestinal bleeding. While some combinations may reduce bleeding complications, others may alter anticoagulant absorption or contribute to clinically significant interaction risks.
Proton pump inhibitors such as omeprazole and lansoprazole are commonly co-prescribed with anticoagulants to reduce upper gastrointestinal bleeding risk, particularly in high-risk patients receiving NSAIDs or antiplatelet therapy. Although generally beneficial, PPIs may still contribute to interactions in certain situations. Omeprazole may modestly increase warfarin activity through CYP2C19 inhibition.
Dabigatran deserves particular attention because its absorption depends on an acidic gastric environment. Concurrent administration with strong acid-suppressing therapy may slightly reduce bioavailability, although this is not usually clinically significant. Episodes of vomiting, diarrhoea, or poor oral intake may additionally destabilise anticoagulant therapy in vulnerable patients.
Antibiotics
Warfarin and CYP-mediated interaction risks
Antibiotics remain among the most clinically significant causes of anticoagulant interactions encountered in everyday pharmacy practice. Interaction severity varies considerably depending on the antimicrobial involved, the anticoagulant prescribed, and individual patient factors such as age, renal function, nutritional status, and concurrent medicines.
Warfarin is particularly vulnerable. to antibiotic interactions because many antimicrobials inhibit hepatic CYP450 enzymes responsible for warfarin metabolism. Macrolides such as clarithromycin, metronidazole, trimethoprim, quinolones, and azole antifungals may significantly increase INR and bleeding risk. Some antibiotics may additionally alter gastrointestinal bacterial synthesis of vitamin K, further potentiating anticoagulant effects.
Although NOACs generally demonstrate fewer antimicrobial interactions than warfarin, important risks still exist. Strong inhibitors of CYP3A4 or P-glycoprotein pathways may increase plasma concentrations and bleeding risk in susceptible patients.
Cardiovascular medicines
Additive bleeding effects and metabolic interactions
Anticoagulated patients frequently receive multiple cardiovascular medicines simultaneously, particularly
in atrial fibrillation, heart failure, and ischaemic heart disease. This creates considerable potential for potentially harmful medicine interactions, especially
Structured counselling and documentation may substantially reduce preventable harm
in elderly patients with polypharmacy and multiple comorbidities.
Concurrent antiplatelet therapy remains one of the most important contributors to anticoagulant-related bleeding. Aspirin and clopidogrel may substantially increase bleeding risk when combined with warfarin or NOACs, particularly following acute coronary syndromes or coronary stenting procedures.
Amiodarone may markedly increase warfarin activity through CYP inhibition, often necessitating warfarin dose reduction and closer INR monitoring. Verapamil and diltiazem inhibit P-glycoprotein pathways and may increase concentrations of certain NOACs, particularly dabigatran. Careful review of cardiovascular polypharmacy remains essential in higher-risk patients.
Part 3: High-risk patient groups and practical pharmacy management
Identifying patients at increased bleeding risk Certain patient groups remain particularly vulnerable to anticoagulant-related complications and require enhanced pharmacy oversight. Elderly patients are especially high risk due to polypharmacy, frailty, reduced renal function, falls risk, and altered pharmacokinetics. In many cases, interaction severity is influenced not only by the anticoagulant itself, but also by multiple coexisting clinical and social factors.
Renal impairment is particularly important in patients receiving NOACs because reduced drug clearance may significantly increase anticoagulant exposure and bleeding risk. Hepatic impairment may additionally affect clotting factor synthesis and drug metabolism, particularly in warfarin- treated patients.
Pharmacists should routinely assess for red flag symptoms, including unexplained bruising, haematuria, melaena, epistaxis, dizziness, or sudden reductions in haemoglobin. Careful
OTC questioning remains essential, particularly regarding analgesics, supplements, and newly initiated medicines. Structured counselling and documentation may substantially reduce preventable harm.
Part 5: Future directions and the evolving role of pharmacists
The expanding clinical role of pharmacists Anticoagulant prescribing continues to evolve rapidly, with NOACs now dominating treatment pathways for atrial fibrillation and venous thromboembolism in many healthcare settings. Although these agents have simplified anticoagulation management in several respects, interaction risks remain clinically important and continue to require careful pharmacist oversight.
Electronic prescribing systems and interaction-alert software have improved medication safety, but they cannot replace individual clinical judgement. Pharmacists remain uniquely positioned to assess OTC purchases, identify duplicate therapies, evaluate renal function considerations, detect potentially dangerous combinations, and identify compliance issues that automated systems may not detect.
Future developments may include wider pharmacist-led anticoagulation clinics, expanded prescribing responsibilities, and increasing use of pharmacogenomics. However, regardless of advances in therapy, the fundamental principle remains unchanged: Anticoagulants provide substantial clinical benefit when used safely, but even relatively minor interactions may have serious consequences if not identified early. Ongoing pharmacist education will remain central to improving patient outcomes.
Patient counselling and adherence considerations Improving anticoagulant safety through education
Good patient counselling plays an important role in helping to prevent avoidable problems with anticoagulant medicines. A lack of patient understanding is still a major cause of preventable bleeding complications.
Counselling should include clear advice regarding signs of bleeding, including unexplained bruising, prolonged nosebleeds, haematuria, melaena, and persistent gastrointestinal symptoms. Patients should also be advised to inform healthcare professionals about anticoagulant use before dental procedures, surgery, vaccinations, or initiation of new medicines. Particular attention should be paid to elderly patients, those with cognitive impairment, and individuals receiving multiple medicines.
Adherence also remains critically important. Missed NOAC doses may rapidly reduce anticoagulant protection because of their shorter half-lives compared with warfarin. Pharmacists should therefore encourage adherence aids where appropriate and regularly reassess patient understanding during routine medication reviews.
Balancing bleeding risk with thrombotic protection Clinical decision-making in anticoagulated patients
One of the greatest challenges in anticoagulation management is balancing the risk of bleeding against the risk of thrombosis. Excessive concern regarding bleeding complications may sometimes result in underuse or inappropriate discontinuation of anticoagulants, thereby exposing patients to preventable stroke or thromboembolic events.
Risk assessment tools such as HAS-BLED and CHA2DS2-VASc are frequently used to guide anticoagulation decisions in atrial fibrillation. Although these scoring systems are useful, they should not replace individual clinical judgement. Factors such as frailty, recurrent falls, renal impairment, alcohol excess, and poor adherence may all influence real-world risk beyond formal scoring systems.
Regular review of medicine appropriateness remains essential, particularly following hospital discharge or major clinical change. Pharmacists should also remain aware that abrupt discontinuation of anticoagulant therapy without suitable clinical supervision may place patients at significant thrombotic risk. Consequently, collaborative communication between pharmacists, prescribers, and anticoagulation clinics remains essential for safe, long-term patient care.
Clinical practice note
From a practical pharmacy perspective, anticoagulant interaction management increasingly depends on proactive patient engagement rather than reactive intervention following adverse events. Many clinically important interactions originate from apparently minor OTC purchases, short antibiotic courses, or supplement use that patients may not consider relevant. Community pharmacists often serve as the final checkpoint before medicine-related harm occurs. As anticoagulant prescribing continues to evolve, structured counselling, regular medication review, and interdisciplinary communication will remain central to maintaining safe and effective anticoagulation therapy in routine clinical practice.
References
1. National Institute for Health and Care Excel- lence (NICE). Atrial fibrillation: diagnosis and management. NICE Guideline NG196. London: NICE; 2021.
2. National Institute for Health and Care Excel- lence (NICE). Venous thromboembolic diseases: Diagnosis, management, and thrombophilia testing. NICE Guideline NG158. London: NICE; 2020.
3. European Society of Cardiology (ESC). 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2024;45(5):1-126.
4. January CT, Wann LS, Calkins H, et al. 2023 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Circulation. 2023;147:e1-e125.
5. Irish Medicines Formulary (IMF). Anticoagu- lant prescribing guidance. Dublin: Irish Pharma- ceutical Healthcare Association; 2025.
6. Health Products Regulatory Authority (HPRA). Direct oral anticoagulants and bleeding risk safety update. Dublin: HPRA; 2024.
7. British National Formulary (BNF). Anticoagu- lants and antiplatelet drugs. London: BMJ Group and Pharmaceutical Press; 2025.
8. Lexicomp Drug Interactions Database. War- farin interaction monograph. Wolters Kluwer Clinical Drug Information; accessed 2026.
9. Stockley IH. Stockley’s Drug Interactions. 13th ed. London: Pharmaceutical Press; 2024.
10. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Chest. 2012;141:e152S-e184S.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivar- oxaban versus warfarin in non-valvular atrial fibrillation. New England Journal of Medicine. 2011;365:883-891.
12. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medi- cine. 2011;365:981-992.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medi- cine. 2009;361:1139-1151.
14. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin for atrial fibrillation. New England Journal of Medicine. 2013;369:2093- 2104.
15. Steffel J, Collins R, Antz M, et al. 2021 Euro- pean Heart Rhythm Association practical guide on NOAC use in atrial fibrillation. Europace. 2021;23:1612-1676.
16. Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs. Chest. 2012;141:e120S- e151S.
17. Douxfils J, Ageno W, Samama CM, et al. Lab- oratory testing in patients treated with direct oral anticoagulants. Thrombosis and Haemosta- sis. 2018;118:437-450.
18. Hylek EM. Complications of oral antico- agulant therapy: bleeding and non-bleed- ing outcomes. Thrombosis Research. 2013;131:S45-S47.
19. Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for management of atrial fibrillation. European Heart Journal. 2020;42:373-498.
20. Makris M, Van Veen JJ, Maclean R. Warfarin anticoagulation reversal. Blood Reviews. 2013;27:1-9.
21. Wittkowsky AK. Effective anticoagulation management and patient education. Pharmaco- therapy. 2011;31:54S-60S.
22. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of anticoagu- lant therapy. Journal of Thrombosis and Haemo- stasis. 2005;3:692-694.
23. Chan FKL, Kyaw MH, Hsiang JC. Risk of gastrointestinal bleeding with antithrombotic therapy. Gastroenterology Clinics of North Ameri- ca. 2021;50:445-459.
24. Abraham NS, NoseworthyPA, Yao X, et al. Gastrointestinal safety of direct oral anticoagu- lants. Gastroenterology. 2017; 152:1014-1022. 25. Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: food, herbal medicines, and drug interactions. Blood Reviews. 2017;31:193-203.
26. Hellfritzsch M, Grove EL, Husted SE, et al. Clinical use of direct oral anticoagulants in the elderly. Drugs and Aging. 2016;33:491-500. 27. Mega JL, Simon T. Pharmacology of antithrombotic drugs. Circulation Research. 2015;116:180-195.
28. Scottish Intercollegiate Guidelines Network (SIGN). Antithrombotics: indications and man- agement. Edinburgh: SIGN; 2023.
29. Pharmaceutical Society of Ireland (PSI). Guidance for pharmacists on medication safety and anticoagulants. Dublin: PSI; 2024.
30. National Centre for Pharmacoeconomics (NCPE). Cost effectiveness of NOAC therapy in atrial fibrillation. Dublin: NCPE; 2023.
